Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
RenovoRx, Inc. reports news on targeted oncology drug delivery, the commercialization of RenovoCath®, and clinical development of its TAMP™ therapy platform. The company is a life-sciences issuer developing localized cancer therapies and commercializing RenovoCath, a patented FDA-cleared drug-delivery device used for temporary vessel occlusion and chemotherapeutic drug infusion.
Recurring updates cover RenovoCath adoption at U.S. cancer centers, intellectual-property protection for the device, financing activity, financial results, and presentations of clinical or pharmacologic data. News also tracks IAG, the investigational intra-arterial gemcitabine product candidate delivered via RenovoCath, including disclosures tied to the TIGeR-PaC trial in locally advanced pancreatic cancer and orphan drug designations for pancreatic and bile duct cancer.
RenovoRx (NASDAQ: RNXT) formed a dedicated RenovoCath Medical Advisory Board (MAB) to guide clinical and market strategy for its FDA-cleared RenovoCath device and TAMP therapy platform. The MAB unites leading U.S. interventional radiology experts to advise on investigator-initiated trials, real-world evidence, and commercialization within cleared indications.
The board will inform ongoing trials including a Phase III TIGeR-PaC study and a post-marketing registry, and support capital-efficient clinical study planning to broaden TAMP applications in hard-to-treat cancers.
RenovoRx (Nasdaq: RNXT) appointed Mark Voll as Chief Financial Officer, effective February 1, 2026. Voll brings 30+ years of financial leadership and experience scaling public companies through IPOs and exits.
He will support commercialization of RenovoCath, provide forward-facing stockholder communications, and help advance the Phase III TIGeR-PaC clinical trial. A transitional finance team will include Ronald B. Kocak and Lilly Huang.
RenovoRx (NASDAQ: RNXT) will present new clinical data on February 6, 2026 at the SIO Annual Scientific Meeting showing that the TAMP™ therapy platform can use a simplified external pressure transducer to obtain reliable intra-arterial pressure measurements during double-balloon RenovoCath procedures.
The study (Abstract 303) showed strong correlation to intravascular pressure wire measurements in a porcine model and found peak pressure is affected by controllable variables like balloon spacing and target vessel diameter, highlighting procedural optimization opportunities.
RenovoRx (Nasdaq: RNXT) announced acceptance of a clinical data abstract for presentation at the 2026 Society of Interventional Oncology Annual Scientific Meeting in Savannah, Feb 4–8, 2026.
The ePoster, presented Feb 6, 2026, examines real-time intravascular pressure measurements using the TAMP therapy platform and the FDA-cleared RenovoCath double-balloon catheter to optimize targeted chemotherapy delivery in solid tumors.
RenovoRx (Nasdaq: RNXT) announced expansion of commercial adoption of its FDA-cleared RenovoCath device from five active U.S. cancer centers in September 2025 to nine as of Jan 20, 2026, including City of Hope Cancer Center and Moffitt Cancer Center. The RenovoCath device enables the company’s TAMP™ localized chemotherapy delivery approach and is being integrated into oncology programs while related physician interviews and patient stories were publicized. RenovoRx reported approximately $900,000 in sales through September 2025 and says it built a dedicated commercial team by end of 2025 to accelerate adoption. Ongoing Phase III TIGeR-PaC trial sites are not counted among current commercial customers but could convert after full enrollment in H1 2026.
RenovoRx (Nasdaq: RNXT) announced that CEO Shaun Bagai will present at the AlphaNorth Capital Event on January 16-18, 2026 in Nassau, Bahamas. Mr. Bagai will provide updates on commercial adoption of RenovoCath (an FDA-cleared targeted drug-delivery device) and progress in the Phase III TIGeR-PaC trial evaluating intra-arterial gemcitabine for locally advanced pancreatic cancer (LAPC). He will also discuss a post-marketing observational registry collecting real-world safety and survival data across solid tumors and support for capital-efficient investigator-initiated trials in pancreatic cancer.
Investor one-on-one meetings can be requested via KCSA Strategic Communications.
RenovoRx (Nasdaq: RNXT) announced new pharmacokinetic (PK) and pharmacodynamic (PD) data from a Phase III TIGeR-PaC sub-study presented at ASCO GI 2026. The 16-patient sub-study compared intra-arterial gemcitabine (IAG) delivered via the TAMP therapy platform (11 patients) to standard IV gemcitabine (5 patients).
Key findings: IAG showed reduced systemic gemcitabine levels, increased inactive metabolite levels, and a correlation between higher metabolite levels and reduced CA 19-9 biomarker. The company says this profile may improve local potency and lower systemic side effects while the TIGeR-PaC trial continues to enroll and evaluates overall survival.
RenovoRx (Nasdaq: RNXT) announced acceptance of a clinical data abstract at the ASCO Gastrointestinal Cancers Symposium 2026 for a pharmacokinetic/pharmacodynamic sub-study of the Phase III TIGeR-PaC trial.
The sub-study, led by Dr. Paula Novelli, compares intra-arterial gemcitabine delivered via RenovoCath (IAG) to standard intravenous gemcitabine in locally advanced pancreatic cancer and reports decreased systemic drug levels consistent with a reduced clinical side-effect profile for the localized TAMP therapy approach.
The poster (Abstract 732, Poster Board K2) will be presented on January 9, 2026 at Moscone West, San Francisco, during Poster Session B.
RenovoRx (Nasdaq: RNXT) announced that CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference on December 9, 2025 at 12:30 P.M. ET. The presentation will cover commercial progress and market adoption of RenovoCath, recent clinical and scientific program updates, and support for investigator‑initiated trials.
The company reported year‑to‑date revenue of approximately $900,000 through September 30, 2025, and will discuss the ongoing Phase III TIGeR‑PaC trial and a post‑marketing registry capturing real‑world safety and effectiveness data. A replay and webcast will be available on the company investor site.
RenovoRx (Nasdaq: RNXT) announced that CEO Shaun Bagai will present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20, 2025 at 2:00 PM ET.
He will review commercial progress for RenovoCath, report year-to-date revenue of approximately $900,000 (as of Sept 30, 2025), and summarize clinical programs including the ongoing Phase III TIGeR-PaC trial for intra-arterial gemcitabine in locally advanced pancreatic cancer, a post-marketing registry capturing real-world safety and effectiveness data, and investigator-initiated studies in borderline resectable and oligometastatic pancreatic cancer. The presentation will cover adoption trends, market traction, and the TAMP therapy platform. Webcast access is provided on the company's investor relations site.